As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...

The prevalence of PH was 12.8% in those hospitalized in 2018 with left heart disease, a lower percentage than found in previous research.

Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Cytokinetics (CYTK – Research Report). The associated price ...

Among the benefits of semaglutide, the GLP-1 receptor agonist may protect against heart failure events in patients with type 2 diabetes and CKD.

Comorbid diabetes was linked to worse functional and mortality outcomes, including maximum oxygen consumption, among patients with heart failure.

HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to ...

A new scientific statement issued today by the Heart Failure Society of America highlights a critical connection between heart failure (HF) and cancer, with shared mechanisms contributing to the ...

A new Scientific Statement published by the Heart Failure Society of America (HFSA) has revealed a critical connection ...

STAT asked 11 experts, including the FDA commissioner, why the world's wealthiest nation is doing so poorly on cardiovascular ...

USA: A recent study has emerged from the REBALANCE-HF randomized clinical trial, exploring the efficacy of endovascular ...

The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.